All In Biotech

Drug Trial Radar · NCT07575984

Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke

A Pilot, Randomized, Multicenter, Comparative, Open-label Study to Evaluate the Clinical, Laboratory, and Instrumental Efficacy and Safety of Mexidol® Solution for Intravenous and Intramuscular Administration, 50 mg/mL (LLC RPC "PHARMASOFT", Russia), and Mexidol® FORTE 250 Film-coated Tablets, 250 mg (LLC RPC "PHARMASOFT", Russia), in the Treatment of Ischemic Stroke in Hyperacute and Acute Periods

Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Nov 4, 2025

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
PharmasoftIndustry
Sponsor type
Industry
First posted
May 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to further define the mechanisms of action of Mexidol® (solution for intravenous and intramuscular injection, 50 mg/ml) and Mexidol® FORTE 250 (film-coated tablets, 250 mg) in the hyperacute and acute periods of ischemic stroke, and to evaluate their impact on clinical and neuroimaging outcomes of the disease.

Conditions

  • Ischemic Stroke

Interventions

  • MexidolDrug

    Phase 1 (Days 1-10): Mexidol® solution, 500 mg (10 ml) twice daily (total daily dose 1000 mg) administered via IV infusion in 100-200 ml of 0.9% NaCl solution for 10 days. Infusion rate: 40-60 drops per minute. Phase 2 (Days 11-70): Mexidol® FORTE 250 film-coated tablets, 250 mg three times daily (total daily dose 750 mg) for 60 days. Administered on top of standard background therapy in accordance with the 2024 Clinical Guidelines of the Ministry of Health of the Russian Federation for Ischemic Stroke and TIA.

  • GlycineDrug

    Glycine, 100 mg sublingual tablets, 1 g (10 tablets) daily for 5 days. Administered on top of standard background therapy in accordance with the 2024 Clinical Guidelines of the Ministry of Health of the Russian Federation for Ischemic Stroke and TIA.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Infarct Volume at Visit 2 (Day 11)Time frame: Day 11 (Visit 2).

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • First City Clinical Hospital named after E.E. Volosevich

    Arkhangelsk, Russia · Recruiting

  • Ivanovo Regional Clinical Hospital

    Ivanovo, Russia · Recruiting

  • Regional Clinical Hospital

    Ryazan, Russia · Recruiting

  • Hospital for War Veterans

    Saint Petersburg, Russia · Recruiting

  • City Hospital № 40 of Kurortny District

    Saint Petersburg, Russia · Recruiting

  • Smolensk Regional Clinical Hospital

    Smolensk, Russia · Recruiting

  • Regional Clinical Hospital

    Tver', Russia · Recruiting

  • Regional Clinical Hospital

    Yaroslavl, Russia · Recruiting

  • Zhukovskiy Regional Clinical Hospital,

    Zhukovskiy, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.